Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buspirone Clear all
Completed Phase 2 Interventional Results available

Buspirone in Parkinson's Disease

NCT02803749
View directory record Official record
Conditions
Parkinson Disease, Anxiety
Interventions
Buspirone, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 1 Interventional

Buspirone for Opioid Tapering

NCT03521960
View directory record Official record
Conditions
Opioid-Related Disorders, Dependency (Psychology), Pain, Chronic, Opiate Withdrawal Syndrome
Interventions
Buspirone oral capsule, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 17, 2026, 8:25 PM EDT
Recruiting Phase 4 Interventional

Buspirone and Melatonin for Depression Following Traumatic Brain Injury

NCT04400266
View directory record Official record
Conditions
Depression, Brain Injuries, Traumatic
Interventions
Buspirone, Mealatonin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 17, 2026, 8:25 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Spinal Cord Neuromodulation for Spinal Cord Injury

NCT02313194
View directory record Official record
Conditions
Cervical Spinal Cord Injury, Tetraparesis, Tetraplegia
Interventions
Epidural Stimulation, Buspirone
Device · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 17, 2026, 8:25 PM EDT
Terminated Phase 1 Interventional Results available

Piloting Acute Care to Primary Care Linkage of Safety Net Patients

NCT01347541
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Cognitive Behavioral Therapy, Motivational Interviewing, FDA-Approved Anti-Anxiety Medications, Standard Care Control
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 4 Interventional

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

NCT00021528
View directory record Official record
Conditions
Depression
Interventions
citalopram, BuproprionSR, buspirone, Lithium, mirtazapine, nortriptyline, sertraline, tranylcypromine, VenlafaxineXR, Cognitive Therapy, T3 (Triiodothyronine)
Drug · Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Chula Vista, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2009 · Synced Oct 17, 2026, 8:25 PM EDT
Terminated Phase 3 Interventional Results available

Buspirone as a Potential Treatment for Recurrent Central Apnea

NCT00746954
View directory record Official record
Conditions
Central Apnea, Heart Failure
Interventions
Acetazolamide, Buspirone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 3 Interventional

Serotonin 1A Agonists and Cognition in Schizophrenia

NCT00178971
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
adjunctive treatment with buspirone, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 17, 2026, 8:25 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

The Intravascular Cooling in the Treatment of Stroke 2/3 Trial

NCT01123161
View directory record Official record
Conditions
Stroke, Acute
Interventions
hypothermia and anti-shivering treatment, Group1: IV t-PA and normothermia
Device · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
22 Years to 82 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)

NCT00705003
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD, BCI-024 (Buspirone), Matching placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Buspirone in Reducing Shortness of Breath in Patients With Cancer

NCT00053846
View directory record Official record
Conditions
Dyspnea, Pulmonary Complications, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
buspirone hydrochloride, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 120 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
15
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 4 Interventional Results available

Buspirone Treatment for Marijuana Dependence

NCT00875836
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 2 Interventional Results available

Improving Ventilatory Capacity in Those With Chronic High Level SCI

NCT05041322
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 2 Interventional

Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1

NCT00149617
View directory record Official record
Conditions
Marijuana Abuse, Mood Disorders
Interventions
Buspirone
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 1 Interventional

Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury

NCT00270959
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Cognitive Behavioral Therapy, Motivational Interviewing, FDA-Approved Anti-Anxiety Medications, Standard Care Control
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 2 Interventional Results available

Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence

NCT01641159
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Buspirone, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Columbus, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Oct 17, 2026, 8:25 PM EDT
Active, not recruiting Phase 2 Interventional

Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury

NCT04458324
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Buspirone Hydrochloride, Buspirone placebo, Noninvasive Ventilation (NIV), Sham Non-invasive ventilation (NIV), Functional Electrical Stimulation Row Training (FESRT)
Drug · Device · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Buspirone Hydrochloride 30mg Tablets, Non-Fasting

NCT00840398
View directory record Official record
Conditions
Healthy
Interventions
BUSPAR® 30 mg Tablet, Buspirone Hydrochloride 30 mg Tablet
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence

NCT00360191
View directory record Official record
Conditions
Marijuana Abuse
Interventions
Buspirone, Motivational enhancement therapy
Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 2 Interventional Results available

Buspirone, Stress, and Attentional Bias to Marijuana Cues

NCT02132832
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Buspirone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Buspirone Hydrochloride 30mg Tablets, Fasting

NCT00840606
View directory record Official record
Conditions
Healthy
Interventions
BUSPAR® 30 mg Tablet, Buspirone Hydrochloride 30 mg Tablet
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 2 Interventional Results available

Buspirone for Early Satiety and Symptoms of Gastroparesis

NCT03587142
View directory record Official record
Conditions
Gastroparesis
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 17, 2026, 8:25 PM EDT
Completed Phase 2 Interventional

Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar

NCT00174226
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Buspirone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2008 · Synced Oct 17, 2026, 8:25 PM EDT
Terminated Phase 1 Interventional

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

NCT02589340
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesias, Movement Disorders
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 17, 2026, 8:25 PM EDT